An Activated Protein C Analog With Reduced Anticoagulant Activity Extends the Therapeutic Window of Tissue Plasminogen Activator for Ischemic Stroke in Rodents

Stroke - United States
doi 10.1161/strokeaha.112.658997
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Tissue Plasminogen Activator-Based Nanothrombolysis for Ischemic Stroke

Expert Opinion on Drug Delivery
Pharmaceutical Science
2017English

Neuroprotective Activities of Activated Protein C Mutant With Reduced Anticoagulant Activity

European Journal of Neuroscience
Neuroscience
2009English

Systemic Review : Role of Tissue Plasminogen Activator for Acute Ischemic Stroke

The Egyptian Journal of Hospital Medicine
2018English

Genome Response to Tissue Plasminogen Activator in Experimental Ischemic Stroke

BMC Genomics
BiotechnologyGenetics
2010English

Early Changes of Tissue Perfusion After Tissue Plasminogen Activator in Hyperacute Ischemic Stroke

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2011English

Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke Be Extended to 4.5 Hours?

Canadian Journal of Hospital Pharmacy
PharmacologyPharmacy
2009English

Pharmacotherapy Updates of Recombinant Tissue Plasminogen Activator (R-Tpa) in Acute Ischemic Stroke

Jentashapir Journal of Health Research
2016English

Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke

Case Reports in Critical Care
2018English

Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Ischemic Stroke Patients Over 80 Years Old: The Fukuoka Stroke Registry

PLoS ONE
Multidisciplinary
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy